Sanofi-Regeneron's Flagship Drug Shows Consistent Efficacy, Safety Profile At Two Years For Asthma In Kids

  • Regeneron Pharmaceuticals Inc REGN and Sanofi SA SNY announced results from a Phase 3 open-label extension trial of Dupixent (dupilumab) as maintenance therapy in asthma patients aged 6 to 11.
  • The trial assessed Dupixent when added to other asthma medications for uncontrolled moderate-to-severe asthma with evidence of type 2 inflammation. 
  • Also read: Regeneron-Sanofi's Dupixent Hits Primary Goal In Esophagitis Patients Below 11 Years.
  • Children treated with Dupixent in the extension trial experienced:
    • Low rate of severe asthma attacks with an average of 0.118-0.124 events per year, compared to 2.16-2.56 events per year at baseline in the pivotal trial.
    • Sustained improvement in lung function at 52 weeks of 9.43-12.6 percentage points from baseline in the pivotal trial.
    • Children who switched from placebo in the pivotal trial to Dupixent in the extension trial demonstrated an improvement of 8.71 percentage points in lung function at two weeks.
    • The safety results of the trial were generally consistent with the known safety profile of Dupixent in its approved respiratory indications. 
  • Price Action: SNY stock is down 0.27% at $39.97 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!